IMNM
Immunome, Inc.
Stock
$20.90+0.01 (+0.05%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $0 | $6.9M | $9.0M | $14M |
| R&D | $206M | $177M | $130M | $23M |
| Operating income | −$270M | −$224M | −$306M | −$110M |
| Net income | −$254M | −$212M | −$293M | −$107M |
| Diluted EPS | −$2.52 | −$2.43 | −$5.00 | −$5.38 |
| Diluted shares | — | 87.4M | 58.6M | 19.8M |
| Revenue growth | — | −23.2% | −35.5% | — |
| Operating margin | — | −3,228.8% | −3,382.4% | −781.4% |
| Net margin | — | −3,060.0% | −3,240.4% | −761.9% |